

Patricia Font

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7055456/publications.pdf>

Version: 2024-02-01

39
papers

1,206
citations

567281

15
h-index

377865

34
g-index

44
all docs

44
docs citations

44
times ranked

1271
citing authors

#	ARTICLE	IF	CITATIONS
1	Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues” Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16
2	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS&Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
3	Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility. International Journal of Hematology, 2022, 115, 61-68.	1.6	8
4	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. Journal of Clinical Oncology, 2021, 39, 48-56.	1.6	80
5	Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 263-277.	1.9	5
6	Next Generation Cytogenetics in Myeloid Hematological Neoplasms: Detection of CNVs and Translocations. Cancers, 2021, 13, 3001.	3.7	2
7	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	7.2	97
8	Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. Molecular Oncology, 2021, 15, 2273-2284.	4.6	5
9	Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia, 2021, 35, 2119-2124.	7.2	74
10	Interobserver Variability with the Diagnosis of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) – Is the Threshold of 20% Bone Marrow Blasts Reproducible?. Blood, 2021, 138, 2607-2607.	1.4	2
11	On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs). Blood, 2021, 138, 2598-2598.	1.4	3
12	Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2020, 136, 17-17.	1.4	4
13	Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).. Journal of Clinical Oncology, 2020, 38, 7506-7506.	1.6	15
14	Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms. Cancers, 2019, 11, 1364.	3.7	23
15	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673.	1.4	66
16	Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment. Blood, 2019, 134, 4248-4248.	1.4	2
17	Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?. Cytometry Part B - Clinical Cytometry, 2018, 94, 527-535.	1.5	9
18	Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive. Blood, 2018, 132, 463-463.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 3085-3085.	1.4	0
20	Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study. <i>European Journal of Cancer Care</i> , 2017, 26, e12426.	1.5	1
21	Multicenter Comparison of CD34+ Myeloid Cell Count by Flow Cytometry in Low-Risk Myelodysplastic Syndrome. Is It Feasible?. <i>Leukemia Research</i> , 2017, 55, S98-S99.	0.8	0
22	Myelodysplastic syndrome after breast cancer. The challenge of late complications in long-term survivors. <i>Leukemia Research</i> , 2016, 49, 88-89.	0.8	2
23	A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7060-7060.	1.6	7
24	Interobserver variance in myelodysplastic syndromes with less than 5% bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2% blasts. <i>Annals of Hematology</i> , 2015, 94, 565-573.	1.8	62
25	A Score Based on IPSS-R, Ferritin and EPO Levels Predicts Erythroid Response to ESAs and Survival in Lower Risk Anemic MDS Patients with High Probability of Response to ESAs: Spresas Sub-Analysis from the GESMD. <i>Blood</i> , 2015, 126, 2896-2896.	1.4	6
26	Azacitidine in Older Patients with Acute Myeloid Leukemia (AML) and Adverse Karyotype. Subanalysis from the Alma Study. <i>Blood</i> , 2014, 124, 945-945.	1.4	0
27	Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. <i>Annals of Hematology</i> , 2013, 92, 19-24.	1.8	65
28	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. <i>Leukemia and Lymphoma</i> , 2013, 54, 472-475.	1.3	66
29	The Challenge Of Quantifying CD34+ Myeloid Cells In Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts. Reproducibility Among 6 Flow Cytometry Observers. <i>Blood</i> , 2013, 122, 2769-2769.	1.4	1
30	Inter-Observer Discordance With The Diagnosis Of Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts: Unilineage Vs Multilineage Dysplasia and Reproducibility Of The Threshold Of 2% Blasts. <i>Blood</i> , 2013, 122, 2768-2768.	1.4	0
31	Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. <i>Leukemia</i> , 2012, 26, 1730-1741.	7.2	217
32	Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators. <i>Blood</i> , 2012, 120, 3593-3593.	1.4	3
33	Azacitidine for the treatment of patients with acute myeloid leukemia with 20%–30% blasts and multilineage dysplasia. <i>Advances in Therapy</i> , 2011, 28, 1-9.	2.9	8
34	P041 Potential value of flow cytometry immunophenotyping in the diagnosis of hypoplastic MDS. <i>Leukemia Research</i> , 2009, 33, S82.	0.8	0
35	Expression of CD7 in myelodysplastic syndromes (MDS): Is this a truly prognostic factor?. <i>Leukemia Research</i> , 2008, 32, 185-186.	0.8	8
36	Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?. <i>Translational Research</i> , 2008, 151, 240-245.	5.0	29

#	ARTICLE	IF	CITATIONS
37	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	3.5	36
38	Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leukemia Research, 2006, 30, 957-963.	0.8	24
39	Plasma endothelin-1 levels after stem cell transplantation. Bone Marrow Transplantation, 2000, 26, 1199-1204.	2.4	6